Biodexa Pharmaceuticals Stock Surges 69% on Syngene Partnership

Apr 02, 2026 15:33 UTC

BDRX

Immediate term

Biodexa Pharmaceuticals' shares jumped 69% following a partnership with Syngene International for manufacturing MTX240 API and dosage form. The stock is currently trading at $1.05 on the Nasdaq.

Biodexa Pharmaceuticals' stock surged 69% following a partnership with Syngene International.
The partnership involves manufacturing MTX240 API and dosage form.
BDRX shares are currently trading at $1.05, up from $0.9235 at the open.
The stock reached an intraday high of $1.35.
The company plans to file an IND and initiate a Phase 1b/2a study by year-end.
The stock has traded between $0.6010 and $19.300 over the past year.

Biodexa Pharmaceuticals Plc (BDRX) experienced a significant surge in its stock price, climbing approximately 69% in morning trading on Thursday after announcing a strategic partnership with Syngene International Ltd. The collaboration involves the manufacturing of both MTX240 active pharmaceutical ingredient and dosage form. As of the latest update, BDRX shares are trading at $1.05 on the Nasdaq, reflecting a substantial increase from the opening price of $0.9235. The stock reached an intraday high of $1.35 during the session. Over the past year, the stock has fluctuated between $0.6010 and $19.300. In addition to the partnership, the company plans to file an Investigational New Drug (IND) application and initiate a Phase 1b/2a study by the end of the year. The partnership and upcoming clinical trials could potentially impact the company's future growth and market position in the pharmaceutical sector.